Importance Oncocytic (Hürthle cell) thyroid carcinoma is a follicular cell-derived neoplasm
that accounts for approximately 5% of all thyroid cancers. Until recently, it was categorized …

We present the case of a 56-year-old male patient diagnosed with Hürthle cell carcinoma
(HCC) that developed widespread metastasis in bone, lung, and lymph nodes with a larger …

Abstract Somatostatin receptor type 2 (SSTR2) and thyroid-stimulating hormone receptor
(TSHR) display variable expression in primary thyroid tumors and have been implicated as …

Context Risk factors for radioactive iodine (RAI)-refractory disease in follicular (FTC) and
oncocytic thyroid carcinoma (OTC) are unknown. Objective The aim of this study is to identify …

Background The management guidelines of radioactive Iodine (RAI) therapy for distinct
types of differentiated thyroid carcinoma (DTC) were the same in clinical practice. However …

Collision tumour of the thyroid is a rare entity for which surgical resection is the primary
treatment. We present here a case of a collision thyroid tumour of oncocytic and papillary …

Background With the release of the 2015 management guidelines, the American Thyroid
Association narrowed the indications for postoperative radioactive iodine (RAI) in well …

Background Oncocytic carcinoma (OTC) is an uncommon and unique form of differentiated
thyroid carcinoma. It was previously termed Hürthle-cell carcinoma and was considered to …

Background Hürthle cell carcinoma (HCC) has traditionally been managed with total
thyroidectomy. However, current evidence suggests a limited benefit to this approach due to …

Background Hürthle-cell carcinoma (HCC) is an uncommon form of differentiated thyroid
cancer representing up to 5% of thyroid malignancies (1). In late 2022, the World Health …